Table 3 Prognostic factors for overall survival (OS): hazard-ratio (HR), CI 95%, and P-value in univariate and multivariate analysis.

From: Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

 

Univariate analysis

Multivariate analysis

Variables

HR

CI 95%

P -value

HR

CI 95%

P -value

Female sex

0.50

(0.21–1.37)

0.20

0.78

(0.24–2.56)

0.69

Synchronous metastases

1.51

(0.63–4.31)

0.34

2.21

(0.74–6.62)

0.16

Serum bilirubin level30 μmol l−1

3.66

(2.50–34.03)

0.002

10.23

(2.51–41.70)

0.001

Positive serology for HBV and/or HCV

2.18

(0.69–12.40)

0.15

6.89

(1.47–32.20)

0.014

Age75 years

0.62

(0.24–1.58)

0.34

   

Underlying cirrhosis

1.22

(0.45–3.39)

0.68

   

Chronic alcoholism

2.13

(0.59–15.84)

0.21

   

Obesity

0.71

(0.24–2.20)

0.58

   

Diabetes

0.81

(0.29–2.18)

0.66

   

CA 19–980 IU ml−1

1.62

(0.64–4.89)

0.29

   
  1. Statistically significant results are shown in bold (P<0.05).